While this effect is beneficial for weight loss helping you feel fuller for longer and reducing overall calorie intake it can also contribute to the variability seen on the scales
Currently, several long-acting dual GLP-1R/GCGR agonists are in various stages of clinical development
Victoza (Liraglutide), Ozempic (Semaglutide), Trulicity (Dulaglutide), Mounjaro (Tirzepatide), and Saxenda (Liraglutide for weight management)
The appetite suppression starts within hours of the first injection
Participants experienced improved recovery, reduced soreness, and lower levels of muscle damage markers like creatine kinase
Supports collagen synthesis, improving skin elasticity